Ion-paired pirenzepine-loaded micelles as an ophthalmic delivery system for the treatment of myopia

Nanomedicine. 2017 Aug;13(6):2079-2089. doi: 10.1016/j.nano.2017.05.001. Epub 2017 May 21.

Abstract

Myopia is one of the most common ocular disorders for which standard treatments, such as refractive surgery, often involve invasive procedures. Pirenzepine (PRZ), a muscarinic receptor antagonist, has been recognized as a promising candidate for the treatment of myopia, but possesses poor ocular bioavailability. The overall objective of this study was to prepare PRZ-sorbic acid complexes suitable to be encapsulated into micelles with high efficiency for optimal ophthalmic delivery. The results demonstrated that sorbic acid, used as the counter ion, had the most significant effects in increasing the octanol-water distribution coefficient of PRZ as well as improving its corneal permeability in vitro among various counter ions tested. In vivo absorption results showed that a 1.5 times higher bioavailability was achieved by the addition of sorbic acid at a 1:1 ratio. Cytotoxicity studies in vitro and biocompatibility studies in vivo indicated that the micelles did not cause significant toxicities to the eyes.

Keywords: And Ophthalmic Delivery; Ion-pair formation; Micelles; PRZ.

MeSH terms

  • Animals
  • Biological Availability
  • Cornea / cytology
  • Cornea / drug effects*
  • Drug Delivery Systems*
  • Humans
  • Micelles*
  • Muscarinic Antagonists / pharmacokinetics
  • Muscarinic Antagonists / pharmacology*
  • Myopia / drug therapy*
  • Myopia / pathology
  • Pirenzepine / pharmacokinetics
  • Pirenzepine / pharmacology*
  • Rabbits
  • Tissue Distribution

Substances

  • Micelles
  • Muscarinic Antagonists
  • Pirenzepine